41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Education and training in the use and operation of medical
and surgical equipment, apparatus and appliances and
instruments, and consultation relating to the selection and
purchase thereof and use in medical care, medical therapy
and surgery. Medical research services. Providing medical information, consultancy and advisory
services; professional consultation in the field of medical
and surgical equipment, apparatus, appliance and
instruments; consultation on medical care, medical therapy
and surgery; consultation services, namely, providing
medical information to medical professionals to assist in
the diagnosis and treatment of patients; medical
consultation with physicians regarding the use of medical
apparatus for treatment of patients; technical consultation
in the field of medical and surgical equipment, apparatus,
appliances and instruments, namely, consultation regarding
the selection and purchase thereof, and the use in providing
medical care, medical therapy and surgery; providing a
patient support program, namely, providing medical
information to patients evaluating therapeutic treatment
options; providing medical information to patients in the
field of surgery preparation; maintaining patient medical
records and files in preparation for surgery; providing
medical advisory and consultancy services concerning medical
coding and medical reimbursement; providing online medical
evaluation services, namely, functional assessment program
for patients who are about to receive medical treatment
services for purposes of guiding treatment and assessing
program effectiveness; home health care services in the
nature of interactive medical care monitoring for patients;
managed healthcare services, namely, providing disease
management programs to others; providing medical information
and healthcare information accessible to healthcare
providers including case studies, peer-reviewed journal
articles and references, via an on-line computer database;
providing medical information for medical professionals via
monitoring devices for purposes of monitoring and diagnosing
medical conditions via a website.
The present invention provides a novel pyrimidine compound represented by Formula [I] and a salt thereof:
The present invention provides a novel pyrimidine compound represented by Formula [I] and a salt thereof:
The present invention provides a novel pyrimidine compound represented by Formula [I] and a salt thereof:
[in the formula, the symbols are as defined in the specification], which is useful for treating, preventing and/or diagnosing seizure and the like in disease involving epileptic seizure or convulsive seizure (including multiple drug resistant seizure, refractory seizure, acute symptomatic seizure, febrile seizure and status epilepticus), as well as a medical use therefor.
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07F 7/08 - Compounds having one or more C—Si linkages
5.
ORALLY ADMINISTERED SUBSTANCE AND METHOD FOR PRODUCING SAME, AND MAGNETIC INK USED TO PRODUCE ORALLY ADMINISTERED SUBSTANCE
Provided is an orally administered substance provided with a magnetic marker that can be detected easily by a magnetic sensor even with a small amount applied. The orally administered substance contains a composition for oral administration and a magnetic marker provided on the composition for oral administration. The magnetic marker contains a magnetic powder and a binder and has a squareness ratio of 0.40 or more.
A61J 3/06 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
A61K 9/44 - Pills, lozenges or tablets printed, embossed, grooved, or perforated
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
The present invention addresses the problem of providing: a method for reprogramming differentiated hair follicle mesenchymal cells to produce stem or progenitor cells of the hair follicle mesenchymal cells; and a composition for preventing or ameliorating the thinning or graying of hair by using a secretion factor derived from the cells. A method for producing hair follicle mesenchymal stem or progenitor cells which solves the problem of the present invention is characterized by comprising bringing hair follicle mesenchymal cells into contact with a ROCK inhibitor in vitro. A composition that solves the problem of the present invention is characterized by containing an exosome or microRNA derived from the cells, and is capable of suppressing losing or graying of hair.
A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
Provided is a novel compound serving as an analogue to be removed from API or a preparation. Further provided is a reference standard of an analogue for use in the quality control of a medicament. Analogue 1: 3-ethyl-4-{4-[4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl]-3,3′-di(propan-2-yl)-1′H-[1,4′-bipyrazolo[3,4-b]pyridin]-1′-yl}benzamide. Analogue 2: 3-ethyl-4-fluorobenzamide. Analogue 3: N-[1-(4-carbamoyl-2-ethylphenyl)-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-3-ethyl-4-{4-[4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl}benzamide. Analogue 4: 3-ethyl-4-{14-[4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl]-13,23,33-tri(propan-2-yl)-31H-[11,24:21,34-terpyrazolo[3,4-b]pyridin]-31-yl}benzamide. Analogue 5: 4,4′-(1H,1′H-[4,4′-biimidazole]-1,1′-diylbis{[3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-4,1-diyl]})bis(3-ethylbenzamide). Analogue 6: 4-{4,6-bis[4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl }-3-ethylbenzonitrile. Analogue 7: 4-{4,6-bis[4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl }-3-ethylbenzamide. Analogue 8: 4-[4-ethoxy-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl]-3-ethylbenzamide. Analogue 9: 3-ethyl-4-[4-methoxy-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl]benzamide.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
C07C 233/65 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
Provided is a novel compound useful for, e.g., comprehensive analysis of cell surface proteins. Disclosed is a functional compound or a salt thereof in which a tyrosine residue reaction site R is linked to a protein purification tag site Tag via a spacer S. The tyrosine residue reaction site R is a group represented by formula (1). (In the formula, * denotes a bond with a spacer S, and R1and R2 are each independently selected from the group consisting of H, alkyl which optionally be substituted with one or more substituents, aryl which optionally be substituted with one or more substituents, and heteroaryl which optionally be substituted with one or more substituents.)
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; lacteal flour for babies; nutritional supplements consisting primarily of proteins, fats and/or carbohydrates in liquid, jelly, gel or powder form; nutritional supplements; dietary supplements for human beings; dietary supplements for human beings, namely, dietary supplement drinks, dietary supplement in liquid, jelly, gel or powder form, and dietary supplement drink mixes; nutritional supplements, namely, powdered nutritional supplement drink mix.
05 - Pharmaceutical, veterinary and sanitary products
29 - Meat, dairy products, prepared or preserved foods
30 - Basic staples, tea, coffee, baked goods and confectionery
32 - Beers; non-alcoholic beverages
Goods & Services
Dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; lacteal flour for babies; nutritional supplements consisting primarily of proteins, fats and/or carbohydrates in liquid, jelly, gel or powder form; nutritional supplements; dietary supplements for human beings; dietary supplements for human beings, namely, dietary supplement drinks, dietary supplement in liquid, jelly, gel or powder form, and dietary supplement drink mixes; nutritional supplements, namely, powdered nutritional supplement drink mix. Jellies for food, other than confectionery; jellies, jams, compotes; gelatine for food; meat jellies; fish jellies; fruit jellies, other than confectionery; vegetable jellies; kanten [dried pieces of agar jelly]; meat jellies containing collagen peptides; fish jellies containing collagen peptides; fruit jellies, other than confectionery, containing collagen peptides; vegetable jellies containing collagen peptides; protein milk; soya milk in jelly; soya-based snack foods; milk-based beverages flavored with coffee; milk-based beverages containing fruit juice; fruit-based, vegetable-based, bean-based or nut-based snacks. Puddings; jellies [confectionery]; bavarian creams; confectionery; bread and buns; porridge; processed grains; boxed lunches consisting of rice, with added meat, fish or vegetables; instant confectionery mixes; ice cream mixes; sherbet mixes; coffee; cocoa; tea; sweets; artificial coffee; pastries; processed cereals; preparations made from rice; wheat, processed; ready-to-eat cereals; gluten-free cereal products; cereal bars. Soft drinks; fruit juices; vegetable juices [beverages]; whey beverages; beer; extracts of hops for making beer; fruit and vegetable smoothies; non-alcoholic beverages for nutritional purposes; non-alcoholic beverages; smoothies; energy drinks; isotonic beverages; soft drinks in jelly [beverages]; fruit juices in jelly [beverages]; vegetable juices in jelly [beverages]; whey beverages in jelly; isotonic beverages in jelly; concentrates, syrups and powders used in the preparation of soft drinks; syrups and other non-alcoholic preparations for making beverages; powders used in the preparation of non-alcoholic beverages for nutritional purposes; powders used in the preparation of fruit-based beverages; syrups for beverages; soft drinks in powder form; fruit juices in powder form; vegetable juices in powder form [beverages]; whey beverages in powder form; isotonic beverages in powder form; non-alcoholic beverages, other than for dietary or medical purposes; powder used in the preparation of non-alcoholic beverages, other than for dietary or medical purposes; soft drink mixes; non-carbonated soft drinks; coffee-flavored soft drinks; fruit-flavored soft drinks; vitamin fortified soft drinks; sports drinks.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations; medicinal drinks; lacteal flour
for babies; nutritional supplements; dietary supplements;
food supplements; nutritional and dietary supplements formed
and packaged as bars; dietary supplement drinks; dietary
supplement drink mixes; dietetic beverages adapted for
medical purposes; dietetic foods adapted for medical
purposes; beverages for babies; food for babies.
14.
FREEZE-DRIED POWDERED GREEN TEA BEVERAGE AND METHOD FOR PRODUCING SAME
The objective of the present invention is to provide a freeze-dried powdered green tea beverage having excellent dispersibility in water, and a method for producing the same. This freeze-dried powdered green tea beverage comprising a freeze-dried product of a liquid composition containing, in water, (A) powdered green tea, (B) water-soluble dietary fiber, and (C) (C1) an amylolytic enzyme-treated product of cereal grains and/or (C2) animal milk has excellent dispersibility in water.
05 - Pharmaceutical, veterinary and sanitary products
35 - Advertising and business services
Goods & Services
Dietary and nutritional supplements; Vitamin and mineral supplements On-line ordering services featuring vitamins, minerals, and nutritional and dietary supplements
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Intravenous fluids used for rehydration, nutrition and the
delivery of pharmaceutical preparations; infusion solutions
for medical purposes; pharmaceutical preparations.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations; diagnostic preparations for
medical purposes; diagnostic reagents for medical use. Providing medical information; medical analysis services for
diagnostic and treatment purposes provided by medical
laboratories; pathological testing for diagnostic or
treatment purposes.
19.
METHODS OF DISPERSING ARIPIPRAZOLE INJECTABLE PREPARATIONS
The present disclosure is directed to methods of dispersing injectable preparations comprising aripiprazole or a salt thereof. Methods of enhancing slidability of containers comprising long-acting injectable preparations comprising aripiprazole or a salt thereof, the methods comprising dispersing ingredients comprised in the preparations before administration, aripiprazole injectable preparations to be administered after the dispersion, methods of administration thereof, and use thereof are provided.
Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
The present invention relates to a microorganism belonging to the genus Akkermansia, having a 16S rRNA gene comprising a nucleotide sequence etc. having homology of more than 98.0% to a nucleotide sequence set forth in SEQ ID NO: 3, having NOD2 agonistic activity, having assimilability to D-mannitol, being a Gram-negative, anaerobic bacterium with a spherical to short rod-shaped form, being negative in an oxidase test, and being positive in a catalase test, and a microorganism for activating NOD2, activating immunity, etc., comprising the microorganism as an active ingredient.
Provided is a pharmaceutical composition containing compound 1, the pharmaceutical composition having excellent disintegratability and bioavailability. The pharmaceutical composition comprises: a granulated product containing 3-ethyl-4-{4-[4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl]-3-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl}benzamide or a pharmaceutically acceptable salt thereof; and crystalline cellulose, and has a disintegration time of within 360 seconds in a coated tablet form.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of central nervous system diseases and disorders; pharmaceutical preparations for the treatment of schizophrenia; pharmaceutical preparations for the treatment of cognitive disorders; pharmaceutical preparations for the treatment of major depressive disorder; pharmaceutical preparations for the treatment of generalized anxiety disorder.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of central nervous system diseases and disorders; pharmaceutical preparations for the treatment of schizophrenia; pharmaceutical preparations for the treatment of cognitive disorders; pharmaceutical preparations for the treatment of major depressive disorder; pharmaceutical preparations for the treatment of generalized anxiety disorder.
A method for detecting conjunctival diseases such as conjunctival MALT lymphoma, and an aging biomarker that serves as an indicator of the aging state of a subject are provided. The method for detecting conjunctival diseases comprises a step of comparing a microbial community structure of a microbiota in an ocular surface tissue specimen sampled from a healthy person with a microbial community structure of a microbiota in an ocular surface tissue specimen sampled from a subject to determine that the ocular surface tissue specimen of the subject has an indication of the conjunctival diseases. The aging biomarker comprises bacterial species which belongs to the Corynebacteriaceae family or the Propionibacteriales family in an ocular surface tissue.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
Disclosed are a method for producing an aripiprazole suspension, wherein the aripiprazole has a mean particle size of 1 to 10 ?m, the method comprising the steps of: (a) combining bulk aripiprazole and a vehicle to form a primary suspension; (b) subjecting the primary suspension to first pulverization using e.g., a high shear pulverizing machine, a dispersion machine that applies shear force to a material to be processed, a colloid mill, an ultrasonic dispersion machine, or a high-pressure jet type emulsifying dispersion machine to form a secondary suspension; and (c) subjecting the secondary suspension to second pulverization using e.g., a high pressure jet type emulsifying dispersion machine to form a sterile final suspension; and a method for producing a freeze dried formulation from the aripiprazole suspension.
The present invention provides a method for treating various diseases with a novel heterocyclic compound represented by Formula [I] and a salt thereof:
The present invention provides a method for treating various diseases with a novel heterocyclic compound represented by Formula [I] and a salt thereof:
The present invention provides a method for treating various diseases with a novel heterocyclic compound represented by Formula [I] and a salt thereof:
wherein the symbols are as defined in the specification, which is useful for treating, preventing and/or diagnosing seizure and the like in disease involving epileptic seizure or convulsive seizure (including multiple drug resistant seizure, refractory seizure, acute symptomatic seizure, febrile seizure and status epilepticus), as well as a medical use therefor.
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 239/47 - One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
C07D 239/54 - Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
The purpose of the present invention is to provide a viscoelastic composition having excellent operability, which is suitable for use in securing the field of view of an endoscope when opaque dark-colored liquid accumulates inside a canal and obstructs the field of view of the endoscope, the viscoelastic composition securing the field of view by pushing the liquid aside, and to provide a method for securing the field of view of an endoscope using the viscoelastic composition. The viscoelastic composition for securing the field of view of an endoscope comprises a substance having viscoelastic properties and water, preferably has a hardness of 550 N/m2 or less, a viscosity (25° C.) of 200 to 2,000 mPa·s, and a loss tangent of 0.6 or less, and more preferably has an electrical conductivity of 250 μS/cm or less. The method for securing the field of view of an endoscope comprises feeding the viscoelastic composition from a proximal part of the endoscope, through a channel, into a distal part of the endoscope.
A61B 1/015 - Control of fluid supply or evacuation
A61B 1/12 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with cooling or rinsing arrangements
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Medicinal drinks; lacteal flour for babies; nutritional supplements; dietary supplements; food supplements; nutritional and dietary supplements formed and packaged as bars; dietary supplement drinks; dietary supplement drink mixes; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; pharmaceutical preparations for the treatment of attention deficit hyperactivity disorder; pharmaceutical preparations for the prevention and treatment of smoking habits and addictions.
The invention provides biomarkers to predict effective treatment of cancer using an IAP antagonist. Identifying one or more of the identified biomarkers in a cancer patient allows a determination to be made whether the patient's cancer is likely to be successfully treated using an IAP antagonist. Accordingly, the invention relates generally to a companion diagnostic for IAP antagonist therapy. In particular, the biomarkers include IL-2Rα, IL-6r, CRP, EPO, CD27, CD40, TN-C, IL-18, PLGF, TNFrl and MCP-4.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
On-line retail store services featuring vitamins, minerals, and nutritional and dietary supplements Vitamin and mineral supplements; Dietary and nutritional supplements
Provided is a composition in the form of a suspension of submicron particles which is useful as a composition comprising Quabodepistat or a salt thereof, etc. Disclosed, as one example of the composition, is a composition comprising at least one selected from the group consisting of Quabodepistat, salts and co-crystals thereof, and solvates thereof. The composition further comprises a suspending agent and a dispersion medium, and takes the form of a suspension of submicron particles.
Provided is a composition in the form of a suspension of submicron particles, which is useful as a composition containing delamanid or a salt thereof. Disclosed as one embodiment of the composition is a composition which contains delamanid or a salt thereof. The composition contains a suspending agent and a dispersion medium and is in the form of a suspension of submicron particles. The suspending agent comprises at least one member selected from the group consisting of Poloxamers and D-α-tocopherol polyethylene glycol succinates.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61P 31/06 - Antibacterial agents for tuberculosis
40.
MESENCHYMAL CELLS OF VENTRAL HINDGUT MESODERM AND METHOD FOR PRODUCING SAME
This method for producing mesenchymal cells of the ventral hindgut mesoderm comprises: culturing pluripotent stem cells in an induction medium A containing a TGF-β inhibitor, a Wnt agonist, and a fibroblast growth factor to induce differentiation into epiblast-like cells; culturing the epiblast-like cells in an induction medium B containing a Wnt agonist, a fibroblast growth factor, and retinoic acid to induce differentiation into caudal epiblast-like cells; culturing the caudal epiblast-like cells in an induction medium C containing a Wnt agonist, a bone morphogenetic protein, and a TGF-β family member to induce differentiation into posterior primitive streak cells; and culturing the posterior primitive streak cells in an induction medium D containing a Wnt agonist, a fibroblast growth factor, a bone morphogenetic protein, and a hedgehog signaling agonist to induce differentiation into mesenchymal cells of the ventral hindgut mesoderm.
Provided is a crystal of a compound having EGFR inhibition ability or a salt thereof, said crystal being excellent in one or more characteristics of stability, hygroscopicity and oral absorbability. One aspect of the present invention provides a crystal form of N-(4-(4-amino-6-ethynyl-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptan-1-yl)-5-methylpyrazine-2-carboxamide the diffraction angle (2θ±0.2°) of which has a peak at a preset angle in the X-ray powder diffraction spectrum.
Provided is a composition in the form of a suspension of microparticles, which is useful as a composition comprising quabodepistat, a salt thereof, or the like. Disclosed as one example of the composition is a composition comprising at least one selected from quabodepistat, a salt thereof, a cocrystal thereof, and solvates of these, wherein the composition contains a suspending agent and a dispersion medium and is in the form of a suspension of microparticles.
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61P 25/00 - Drugs for disorders of the nervous system
44.
COMPOSITION FOR PREVENTING OR TREATING DETERIORATION IN BRAIN FUNCTION OR MAINTAINING OR IMPROVING BRAIN FUNCTION
The present invention aims to provide a method for evaluating dementia and a composition for preventing or treating deterioration in brain function, or for maintaining or improving brain function, and compared the gut microbiota of healthy individuals, individuals with mild cognitive impairment, and individuals with Alzheimer's disease. As a result, gut microorganisms were selected, such as microorganisms belonging to the genus Faecalibacterium, that are associated with cognitive function. Furthermore it was revealed that Faecalibacterium prausnitzii, possessing specific DNA, exhibited an improvement effect against brain function deterioration, such as learning and memory disorders.
A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
45.
METHOD FOR PRODUCING 7H-PYRROLO[2,3-D]PYRIMIDINE-4-AMINE DERIVATIVE
The present invention provides a method for producing a compound represented by formula (I) suitable for mass synthesis as API. Provided according to one aspect of the present invention is a method for producing a compound represented by formula (I) or a salt thereof, the method including deprotecting a protecting group represented by R1 in formula (II) under basic conditions to thereby form a compound represented by formula (I) or a salt thereof.
The present invention provides a method for producing a compound represented by formula (I) suitable for mass synthesis as API. Provided according to one aspect of the present invention is a method for producing a compound represented by formula (I) or a salt thereof, the method including deprotecting a protecting group represented by R1 in formula (II) under basic conditions to thereby form a compound represented by formula (I) or a salt thereof.
Disclosed are compounds, or salts thereof, with sortilin-binding inhibitory activity, medical use thereof for treating, preventing, and/or diagnosing diseases associated with sortilin ligands, and methods of preparing said compounds, or salts thereof. Provided is a compound of formula (I), or a salt thereof, wherein R1is H, etc.; R21-6 1-6 alkyl, etc.; R322 or O; R41-6 1-6 alkyl; and Ring A is optionally substituted partially unsaturated or unsaturated 7- to 15-membered bicyclic or tricyclic heterocyclyl.
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Diagnostic preparations for medical purposes; diagnostic reagents for medical use Providing medical information; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; pathological testing for diagnostic or treatment purposes.
48.
SYRINGE FOR CRYOPRESERVATION OF CELLS, NUCLEIC ACIDS, OR PROTEINS
According to the present invention, a syringe for cryopreservation of cells, a nucleic acid, or a protein comprising: a barrel having a spout and an opening and for containing cells, a nucleic acid, or a protein; a gasket slidably accommodated in the barrel; a plunger connected to the gasket; and a cap that seals the spout of the barrel, wherein the barrel is formed from a fluororesin, and the gasket is formed from a fluororesin or a polyethylene resin. The syringe is excellent in usability, durability, and safety.
It is to provide a liquid for cryopreserving a cell that can effectively suppress cell death caused by freezing and thawing of a mammalian cell and that can effectively increase the proliferation ability of the mammalian cell after freezing and thawing, and a method for cryopreserving a mammalian cell using the liquid for cryopreserving a cell. A liquid comprising 2.5 to 8.75 (v/v) % propylene glycol is used as a liquid for cryopreserving a mammalian cell.
To provide a method for producing a sheet-like cell culture showing a three-layer structure including a cell layer of superficial cells, a cell layer of intermediate cells, and a cell layer of basal cells, in this order. Provided is a method for producing a sheet-like cell culture that includes culturing a progenitor cell population in a second compartment separated from a first compartment via a porous member to form a sheet-like cell culture in the second compartment. The sheet-like cell culture includes a cell layer of superficial cells derived from the progenitor cell population, a cell layer of intermediate cells derived from the progenitor cell population, and a cell layer of basal cells derived from the progenitor cell population, in this order. The first compartment holds an induction medium containing retinoic acid, bone morphogenetic protein (BMP), and fibroblast growth factor (FGF).
The purpose of the present invention is to enable prescription of a gelled nutritional composition to which stricter sterilization conditions can be applied. This gelled nutritional composition contains a protein, a carbohydrate, a mineral, and a gelling agent, and has a viscosity of 6,500-18,000 mPa·s. The protein contains a collagen peptide together with a protein selected from the group consisting of milk-derived proteins and plant-derived proteins, whereby aggregation can be suppressed even under stricter sterilization conditions.
A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
A23L 29/256 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing gelling or thickening agents of vegetable origin from seaweeds, e.g. alginates, agar or carrageenan
An object of the present invention is to provide a rubber composition that can improve reinforcement and heat resistance while also improving fuel efficiency, when carbon black and silica are blended with natural rubber, for example, in application in tires. The rubber composition contains a rubber component, a hydrazone compound, carbon black, silica, and 3-octanoylthio-1-propyltriethoxysilane, wherein natural rubber is present in an amount of 50 parts by mass or more in 100 parts by mass of the rubber component; per 100 parts by mass of the rubber component, the hydrazone compound is present in an amount of 0.1 parts by mass to 2 parts by mass, the carbon black is present in an amount of 15 parts by mass to 60 parts by mass, and the silica is present in an amount of 18 parts by mass to 80 parts by mass; and per 100 parts by mass of the silica, the 3-octanoylthio-1-propyltriethoxysilane is present in an amount of 3 parts by mass to 10 parts by mass.
Provided is a content processing method for determining a degree of priority of presentation of each of a plurality of contents, comprising: identifying the plurality of contents; receiving a first set including contents given positive evaluations and a second set including contents given negative evaluations from among the plurality of contents; extracting a first word set included in the first set and a second word set included in the second set; identifying a plurality of keywords including a plurality of positive keywords related to the first set and a plurality of negative keywords related to the second set according to a first evaluation criterion, the plurality of positive keywords being identified based on the first word set, the plurality of negative keywords being identified based on the second word set; giving weights to the plurality of keywords according to a second evaluation criterion so as to give a weight of zero or more to each of the plurality of positive keywords and give a weight of zero or less to each of the plurality of negative keywords; deriving a total for each of the plurality of contents by summing, over the plurality of keywords, a product of a frequency of appearance of each of the plurality of keywords and the given weight for the each of the plurality of keywords to obtain the total for each of the plurality of contents; and determining the degree of priority of presentation of each of the plurality of contents based on the total for the each of the plurality of contents.
The present invention provides a two-liquid mixture type infusion preparation in which precipitation is unlikely to occur even due to a change in composition upon addition of a calcium ion correction liquid. Provided as a solution is an infusion preparation which is for administration to a peripheral vein, which has two chambers that are separated by a partition that allows for communication, in which a first chamber infusion containing an amino acid is accommodated in a first chamber, and in which a second chamber infusion containing a sugar is accommodated in a second chamber, wherein a liquid mixture of the first chamber infusion and the second chamber infusion has (A) a pH of not more than 6.4 and (B) contains an organic acid in a total amount of not less than 3 mEq/L.
Provided is a crystal of a specific oxazole compound that has specific inhibitory activity against PDE4, and that shows excellent stability. Specifically, provided is a crystal of an oxazole compound represented by formula (5)
Provided is a crystal of a specific oxazole compound that has specific inhibitory activity against PDE4, and that shows excellent stability. Specifically, provided is a crystal of an oxazole compound represented by formula (5)
Provided is a crystal of a specific oxazole compound that has specific inhibitory activity against PDE4, and that shows excellent stability. Specifically, provided is a crystal of an oxazole compound represented by formula (5)
wherein the crystal has peaks at diffraction angles 2θ(°) of 9.6±0.2, 19.1±0.2, and 21.2±0.2 in an X-ray powder diffraction pattern measured using Cukα characteristic X-rays.
C07D 263/32 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
58.
AGENT FOR PREVENTING OR TREATING STEROID OSTEOPOROSIS
The problem addressed is to provide an agent for preventing or treating steroid osteoporosis. The problem is solved by an agent for preventing or treating steroid osteoporosis that contains a Piezo1 and/or an Hes1 enhancer.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
The purpose of the present invention is to provide a rubber composition having, in a vulcanized rubber, superior low heat generation properties (low fuel consumption properties). The rubber composition comprises a rubber component, and a compound represented by formula (1) and/or a salt thereof. Also provided is a heat generation reduction agent for rubber.
An object of the present invention is to provide a sustained-release injectable preparation which is in a medication administration form that can provide the effect of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for a prolonged period of time, the preparation releasing a therapeutically effective amount of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for at least one week. The present invention provides an injectable preparation containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, which releases the active ingredient in such a manner that its blood concentration is maintained for at least one week.
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
61.
METHOD FOR PRODUCING SULFATED POLYSACCHARIDE AND METHOD FOR PRODUCING PAPS
The invention provides a method for producing a sulfated polysaccharide by generating a sulfated polysaccharide by incorporating, in a reaction solution in the presence of ATP or an ATP source, a sulfate ion source, and N-sulfoheparosan, a transformant (a) of a bacterium of the genus Corynebacterium, comprising at least a gene encoding an ATP sulfurylase and a gene encoding an APS kinase, and at least one selected from a transformant (b) of a microorganism belonging to prokaryotes, comprising at least a gene encoding a C5-epimerase, a transformant (c) of a microorganism belonging to prokaryotes, comprising at least a gene encoding a 2-O-sulfotransferase, a transformant (d) of a microorganism belonging to prokaryotes, comprising at least a gene encoding a 6-O-sulfotransferase, and a transformant (e) of a microorganism belonging to prokaryotes, comprising at least a gene encoding a 3-O-sulfotransferase.
The present invention relates to a composition for improving the function of the liver, said composition containing a Japanese horseradish (wasabi) extract obtained using an organic solvent.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical preparations for the treatment of central nervous system diseases and disorders, containing electronic chips which transmit information about drug ingestion by the patient Computer application software for mobile phones, tablets, portable electronic devices and handheld computers for use in collecting and storing patient data and medical information including drug ingestion information, pulse, heart rate, respiratory rate, body temperature, electric pressure in the body, human motion, human position or sleeping condition from a sensor attached to the patient's body. Sensor patches attached to the patient's body for use in measuring, collecting and storing patient data and medical information including drug ingestion information, pulse, heart rate, respiratory rate, body temperature, electric pressure in the body, human motion, human position or sleeping condition.
64.
2'-DEOXY-2',2'-DIFLUOROTETRAHYDROURIDINES WITH HIGH PURITY AND METHODS OF MAKING THE SAME
The invention relates to methods of synthesizing 2′-deoxy-2′,2′-difluorotetrahydrouridine with increased purity and uniform particle size distribution. In particular, methods of the invention include crystallization and isolation procedures rendering synthetic reaction intermediates. The invention further includes compositions comprising the final compound in highly pure form, including lower number of impurities and lower levels of individual and total impurities.
The present disclosure relates to novel crystalline forms of sulfonamide compounds, pharmaceutical compositions containing the crystalline form compounds and methods of preparing and using the same.
C07D 271/113 - 1,3,4-OxadiazolesHydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
A61K 9/00 - Medicinal preparations characterised by special physical form
66.
LIQUID CRYSTAL POLYMER COMPOSITION, LIQUID CRYSTAL POLYMER MOLDED BODY, CAMERA MODULE, AND ELECTRICAL AND ELECTRONIC EQUIPMENT
Provided is a liquid crystal polymer composition that, in relation to sliding between a liquid crystal polymer molded body thereof and a metal material, is capable of reducing the friction coefficient to a low level both at an early stage of the sliding and after the sliding has been repeated multiple times. This liquid crystal polymer composition comprises a liquid crystal polymer (A), a first inorganic filler (B1), a second inorganic filler (B2), and a solid lubricant (C). A treatment layer composed of a hydrophilic surface treatment agent is provided on the surface of the first inorganic filler (B1), and a treatment layer composed of a hydrophobic surface treatment agent is provided on the surface of the second inorganic filler (B2).
C08L 101/12 - Compositions of unspecified macromolecular compounds characterised by physical features, e.g. anisotropy, viscosity or electrical conductivity
C08K 3/01 - Use of inorganic substances as compounding ingredients characterised by their specific function
C08K 3/30 - Sulfur-, selenium-, or tellurium-containing compounds
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of tumor; pharmaceutical preparations for the treatment of cancer; anti-cancer preparations; tumor suppressing agents; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for the treatment of cardiovascular diseases and disorders; pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical preparations for the treatment of dermatological diseases and disorders; pharmaceutical preparations for the treatment of muscular diseases and disorders; pharmaceutical preparations for the treatment of urological diseases and disorders; pharmaceutical preparations for the treatment of digestive diseases and disorders; pharmaceutical preparations for the treatment of gastroesophageal reflux diseases and disorders; pharmaceutical preparations for the treatment of hepatic diseases and disorders; pharmaceutical preparations for the treatment of renal diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of immune diseases and disorders; immunomodulators; immunosuppressive agents; pharmaceutical preparations for the treatment of diseases of the central and peripheral nervous system; pharmaceutical preparations for the treatment of rheumatoid arthritis; pharmaceutical preparations for the treatment of diseases of the blood; pharmaceutical preparations for treating hematological disorders; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for use in chemotherapy; anti-emetic medicines; pharmaceutical preparations for the treatment of pain; analgesic preparations; antiphlogistic preparations; chemical preparations for pharmaceutical purposes; diagnostic reagents for medical purposes in the field of oncology.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of tumor; pharmaceutical preparations for the treatment of cancer; anti-cancer preparations; tumor suppressing agents; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for the treatment of cardiovascular diseases and disorders; pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical preparations for the treatment of dermatological diseases and disorders; pharmaceutical preparations for the treatment of muscular diseases and disorders; pharmaceutical preparations for the treatment of urological diseases and disorders; pharmaceutical preparations for the treatment of digestive diseases and disorders; pharmaceutical preparations for the treatment of gastroesophageal reflux diseases and disorders; pharmaceutical preparations for the treatment of hepatic diseases and disorders; pharmaceutical preparations for the treatment of renal diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of immune diseases and disorders; immunomodulators; immunosuppressive agents; pharmaceutical preparations for the treatment of diseases of the central and peripheral nervous system; pharmaceutical preparations for the treatment of rheumatoid arthritis; pharmaceutical preparations for the treatment of diseases of the blood; pharmaceutical preparations for treating hematological disorders; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for use in chemotherapy; anti-emetic medicines; pharmaceutical preparations for the treatment of pain; analgesic preparations; antiphlogistic preparations; chemical preparations for pharmaceutical purposes; diagnostic reagents for medical purposes in the field of oncology.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of tumor; pharmaceutical preparations for the treatment of cancer; anti-cancer preparations; tumor suppressing agents; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for the treatment of cardiovascular diseases and disorders; pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical preparations for the treatment of dermatological diseases and disorders; pharmaceutical preparations for the treatment of muscular diseases and disorders; pharmaceutical preparations for the treatment of urological diseases and disorders; pharmaceutical preparations for the treatment of digestive diseases and disorders; pharmaceutical preparations for the treatment of gastroesophageal reflux diseases and disorders; pharmaceutical preparations for the treatment of hepatic diseases and disorders; pharmaceutical preparations for the treatment of renal diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of immune diseases and disorders; immunomodulators; immunosuppressive agents; pharmaceutical preparations for the treatment of diseases of the central and peripheral nervous system; pharmaceutical preparations for the treatment of rheumatoid arthritis; pharmaceutical preparations for the treatment of diseases of the blood; pharmaceutical preparations for treating hematological disorders; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for use in chemotherapy; anti-emetic medicines; pharmaceutical preparations for the treatment of pain; analgesic preparations; antiphlogistic preparations; chemical preparations for pharmaceutical purposes; diagnostic reagents for medical purposes in the field of oncology.
70.
HEAT-RESISTANT COATED ARTICLE AND METHOD FOR PRODUCING THE SAME
Provided is a heat-resistant coated article excellent in both heat resistance and water resistance. A heat-resistant coated article 1 comprises: a base material 2; a first coating film 3 provided on a surface 2a of the base material 2; and a second coating film 4 provided on the first coating film 3. The first coating film 3 is a heat-cured product of a composition containing an alkali metal silicate and inorganic particles. The second coating film 4 is a cured product formed by an alkali metal silicate and an acidic curing agent.
B32B 9/00 - Layered products essentially comprising a particular substance not covered by groups
B05D 1/38 - Successively applying liquids or other fluent materials, e.g. without intermediate treatment with intermediate treatment
B05D 3/02 - Pretreatment of surfaces to which liquids or other fluent materials are to be appliedAfter-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials by baking
B05D 5/00 - Processes for applying liquids or other fluent materials to surfaces to obtain special surface effects, finishes or structures
B05D 7/24 - Processes, other than flocking, specially adapted for applying liquids or other fluent materials to particular surfaces or for applying particular liquids or other fluent materials for applying particular liquids or other fluent materials
B32B 15/04 - Layered products essentially comprising metal comprising metal as the main or only constituent of a layer, next to another layer of a specific substance
C09D 1/02 - Coating compositions, e.g. paints, varnishes or lacquers, based on inorganic substances alkali metal silicates
In order to provide a novel cancer treatment method using a FTD-TPI combination drug that exhibits markedly excellent anti-tumor effects with fewer side effects, the present invention provides an anti-tumor agent characterized in that the FTD.TPI combination drug and a taxane compound are administered in combination.
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of tumor;
pharmaceutical preparations for the treatment of cancer;
anti-cancer preparations; tumor suppressing agents;
pharmaceutical preparations and substances for use in
oncology; pharmaceutical preparations for the treatment of
cardiovascular diseases and disorders; pharmaceutical
preparations for the treatment of respiratory diseases and
disorders; pharmaceutical preparations for the treatment of
dermatological diseases and disorders; pharmaceutical
preparations for the treatment of muscular diseases and
disorders; pharmaceutical preparations for the treatment of
urological diseases and disorders; pharmaceutical
preparations for the treatment of digestive diseases and
disorders; pharmaceutical preparations for the treatment of
gastroesophageal reflux diseases and disorders;
pharmaceutical preparations for the treatment of hepatic
diseases and disorders; pharmaceutical preparations for the
treatment of renal diseases and disorders; pharmaceutical
preparations for the treatment of autoimmune diseases and
disorders; pharmaceutical preparations for the treatment of
immune diseases and disorders; immunomodulators;
immunosuppressive agents; pharmaceutical preparations for
the treatment of diseases of the central and peripheral
nervous system; pharmaceutical preparations for the
treatment of rheumatoid arthritis; pharmaceutical
preparations for the treatment of diseases of the blood;
pharmaceutical preparations for treating hematological
disorders; pharmaceutical preparations for the treatment of
allergies; pharmaceutical preparations for use in
chemotherapy; anti-emetic medicines; pharmaceutical
preparations for the treatment of pain; analgesic
preparations; antiphlogistic preparations; pharmaceutical
preparations; chemical preparations for pharmaceutical
purposes; chemical reagents for medical purposes in the
field of oncology.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of tumor;
pharmaceutical preparations for the treatment of cancer;
anti-cancer preparations; tumor suppressing agents;
pharmaceutical preparations and substances for use in
oncology; pharmaceutical preparations for the treatment of
cardiovascular diseases and disorders; pharmaceutical
preparations for the treatment of respiratory diseases and
disorders; pharmaceutical preparations for the treatment of
dermatological diseases and disorders; pharmaceutical
preparations for the treatment of muscular diseases and
disorders; pharmaceutical preparations for the treatment of
urological diseases and disorders; pharmaceutical
preparations for the treatment of digestive diseases and
disorders; pharmaceutical preparations for the treatment of
gastroesophageal reflux diseases and disorders;
pharmaceutical preparations for the treatment of hepatic
diseases and disorders; pharmaceutical preparations for the
treatment of renal diseases and disorders; pharmaceutical
preparations for the treatment of autoimmune diseases and
disorders; pharmaceutical preparations for the treatment of
immune diseases and disorders; immunomodulators;
immunosuppressive agents; pharmaceutical preparations for
the treatment of diseases of the central and peripheral
nervous system; pharmaceutical preparations for the
treatment of rheumatoid arthritis; pharmaceutical
preparations for the treatment of diseases of the blood;
pharmaceutical preparations for treating hematological
disorders; pharmaceutical preparations for the treatment of
allergies; pharmaceutical preparations for use in
chemotherapy; anti-emetic medicines; pharmaceutical
preparations for the treatment of pain; analgesic
preparations; antiphlogistic preparations; pharmaceutical
preparations; chemical preparations for pharmaceutical
purposes; chemical reagents for medical purposes in the
field of oncology.
74.
BRAIN-MIGRATING TUMOR TREATMENT AGENT CONTAINING, AS ACTIVE INGREDIENT, N-(4-(4-AMINO-6-ETHYNYL-5-(QUINOLIN-3-YL)-7H-PYRROLO[2,3-D]PYRIMIDIN-7-YL) BICYCLO[2.2.1]HEPTAN-1-YL)-5-METHYLPYRAZINE-2-CARBOXAMIDE OR SALT THEREOF
The present invention provides a brain-migrating anti-tumor agent that exhibits brain migration ability and EGFR inhibitory activity. One embodiment of the present invention provides a brain-migrating anti-tumor agent comprising, as an active ingredient, N-(4-(4-amino-6-ethynyl-5-(quinolin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl) bicyclo[2.2.1]heptan-1-yl)-5-methylpyrazine-2-carboxamide or a salt thereof.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of tumor; pharmaceutical preparations for the treatment of cancer; chemical reagents for medical purposes in the field of oncology; pharmaceutical preparations for the treatment of cardiovascular diseases and disorders; pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical preparations for the treatment of dermatological diseases and disorders; pharmaceutical preparations for the treatment of muscular diseases and disorders; pharmaceutical preparations for the treatment of urological diseases and disorders; pharmaceutical preparations for the treatment of digestive diseases and disorders; pharmaceutical preparations for the treatment of gastroesophageal reflux diseases and disorders; pharmaceutical preparations for the treatment of hepatic diseases and disorders; pharmaceutical preparations for the treatment of renal diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of diseases of the central and peripheral nervous system; pharmaceutical preparations for the treatment of rheumatoid arthritis; pharmaceutical preparations for the treatment of diseases of the blood; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for use in chemotherapy; anti-emetic medicines; pharmaceutical preparations for the treatment of pain; analgesic preparations; antiphlogistic preparations, namely, pharmaceutical preparations for the treatment of inflammation
Provided is a computer program, an information processing device, and a method that are used to estimate a health state of a target user based on a history of behaviors executed by the target user, and have at least partially improved performance.
Provided is a computer program, an information processing device, and a method that are used to estimate a health state of a target user based on a history of behaviors executed by the target user, and have at least partially improved performance.
According to one embodiment, a computer program can cause, by being executed at least one processor, the at least one processor to function to: acquire target behavior data for identifying a history of behavior executed by a target user; and output, from an estimation model generated by executing supervised learning, target sleep state data for identifying a sleep state of the target user, the target sleep state data including at least one of target property data for identifying a sleep property of the target user, target rhythm data for identifying a sleep rhythm of the target user, target time data for identifying a sleep time of the target user, and target category data for identifying a sleep category to which the target user belongs, by inputting the target behavior data to the estimation model.
G16H 20/60 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
78.
METHODS OF TREATING CANCER WITH IAP ANTAGONIST COMPOUNDS AND COMBINATION THERAPIES
The present disclosure relates generally to use of a compound of formula (I), also named ASTX660 in combination therapies for treating cancer, in particular leukemia.
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61P 35/02 - Antineoplastic agents specific for leukemia
To provide a member for cutting work that is excellent in cutting workability and can suppress the occurrence of burrs when performing cutting work such as scraping, cutting, or drilling a hole using a mechanical tool. The member for cutting work is made from a molded body of a resin composition containing a thermoplastic resin (A) and a reinforcing material (B) and is characterized in that the thermoplastic resin (A) is a crystalline thermoplastic resin, the reinforcing material (B) is an inorganic reinforcing material having a Mohs hardness of 5 or less, and a cutting property parameter defined by formula (1) from the fracture toughness K1c and flexural modulus of the member for cutting work is 20 m1/2to 180 m1/2. Cutting parameter=(fracture toughness K1c/flexural modulus)×105 … Formula (1)
Provided is a member for machining which, when machined by shaving, cutting, or drilling, for example, using a mechanical tool, exhibits excellent machinability and suppresses generation of burrs. The member for machining is composed of a molded object of a resin composition containing a thermoplastic resin (A) and a reinforcing material (B), and is characterized in that: the thermoplastic resin (A) is an amorphous thermoplastic resin; the reinforcing material (B) is an inorganic reinforcing material having a Mohs hardness of 5 or less; and a machinability parameter defined by equation (1) from the fracture toughness K1c and flexural modulus of the member for machining is 15 m1/2to 100 m1/2. Equation (1): Machinability parameter = (fracture toughness K1c)/(flexural modulus)×105
Medical device systems for use in renal denervation and other forms of neuromodulation of the autonomic nervous system, consisting of guiding catheters, medical guidewires, medical introducers; Medical devices, medical device systems consisting of medical devices, medical apparatus, and medical instruments, all for treating heart failure, chronic kidney disease, end stage renal disease, myocardial infarction, anxiety, contrast nephropathy, diabetes, metabolic disorder and insulin resistance; energy emitting catheter-based systems consisting of medical devices and devices for medical procedures in the nature of neuromodulation and denervation of the autonomic nervous system for use in treating a variety of medical conditions, also consisting of guiding catheters, medical guidewires, medical introducers
82.
COMBINATIONS COMPRISING BREXPIPRAZOLE OR A SALT THEREOF AND A SECOND DRUG FOR USE IN THE TREATMENT OF A CNS DISORDER
The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (I) a compound which is 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected from the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracyclic antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination.
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
An oil-in-water emulsion composition that has zinc chloride as an active component and provides excellent separation inhibiting properties and/or drug release properties. The oil-in-water emulsion composition comprises: (A) not less than 30 wt % of zinc chloride; (B) an oily base selected from the group consisting of hydrocarbon oils and higher alcohols; (C) a non-ionic surfactant; and (D) an aqueous base selected from the group consisting of water and polyalcohols. The content of (B) with respect to 100 parts by weight of the components (B) and (C) combined is not less than 52 parts by weight. The content of (B) with respect to 100 parts by weight of the component (B) and the component (D) combined is not less than 11.7 parts by weight. The oil-in-water emulsion composition has excellent separation inhibiting properties. When the component (D) is water and polyethylene glycol, the oil-in-water emulsion composition has excellent drug release properties.
Embodiments of the present invention provide solid oral dosage forms that upon daily administration to a subject provide plasma levels of decitabine with a 5-day AUC for decitabine that is equivalent to the 5-day AUC for a daily IV dose of decitabine of 20 mg/m2 administered as a one hour (1 h) infusion. Also provided according to embodiments of the present invention are solid oral dosage forms wherein upon daily administration to a subject provides a pharmacodynamic effect that is equivalent to the pharmacodynamic effect for a daily intravenous dose of decitabine of 20 mg/m2 administered as a one hour (1 h) infusion. Also provided are methods of treatment using a solid oral dosage form according to an embodiment of the invention.
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
A viscoelastic composition for securing the field of view of an endoscope, the viscoelastic composition comprising a thickening substance and water and having a shear storage modulus G′ of 0.7 Pa or more, and a method for securing the field of view of an endoscope, the method comprising feeding the viscoelastic composition from a proximal part of the endoscope, through a channel, into a distal part of the endoscope.
A61L 31/14 - Materials characterised by their function or physical properties
A61B 1/012 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor characterised by internal passages or accessories therefor
An object of the present disclosure is to provide a crystalline form of 3-(15-methoxypentadecyl)-2, 4, 4-trimethylcyclohex-2-en-1-one, the crystalline form having excellent stability and being preferable in terms of production. The present disclosure provides a crystalline form having characteristic peaks at diffraction angles) (2θ+0.2° of 7.0°, 14.0°, 17.5°, 19.5°, 21.0°, 23.7°, and 24.8° in a powder X-ray diffraction spectrum (CuKα).
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Education and training in the use and operation of medical and surgical equipment, apparatus and appliances and instruments, and consultation relating to the selection and purchase thereof and use in medical care, medical therapy and surgery Medical research services; providing an online computer database, namely, a repository of information in the field of medical data and healthcare information accessible to healthcare providers, including clinical studies, case studies, peer-reviewed journal articles and references Providing medical information, consultancy and advisory services; professional consultation in the field of medical and surgical equipment, apparatus, appliance and instruments; consultation on medical care, medical therapy and surgery; consultation services, namely, providing medical information to medical professionals to assist in the diagnosis and treatment of patients; medical consultation with physicians regarding the use of medical apparatus for treatment of patients; technical consultation in the field of medical and surgical equipment, apparatus, appliances and instruments, namely, consultation regarding the selection and purchase thereof, and the use in providing medical care, medical therapy and surgery; providing a patient support program, namely, providing medical information to patients evaluating therapeutic treatment options; providing medical information to patients in the field of surgery preparation; maintaining patient medical records and files in preparation for surgery; providing medical advisory and consultancy services concerning medical coding and medical reimbursement; providing online medical evaluation services, namely, functional assessment program for patients who are about to receive medical treatment services for purposes of guiding treatment and assessing program effectiveness; home health care services in the nature of interactive medical care monitoring for patients; managed healthcare services, namely, providing disease management programs to others; providing an on-line computer database, namely, a repository of information in the field of medical and healthcare information, including clinical studies, case studies, peer-reviewed journal articles, and references, accessible to healthcare providers; providing a website featuring medical information via monitoring devices for purposes of monitoring and diagnosing medical conditions by medical professionals
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
Goods & Services
Soap; cosmetic soaps; dentifrices; toilet water; lotions for
cosmetic purposes; skin lotion; hair lotion; body lotion;
wave-set lotions; perfumery, other than perfumes for
personal use; incense; false nails; false eyelashes.
According to the present invention, a syringe comprising a barrel having a spout and an opening; a gasket slidably accommodated in the barrel; a plunger connected to the gasket; and a cap that seals the spout of the barrel, wherein the opening of the barrel is sealed only with the gasket. The syringe is excellent in usability, durability, and safety.
A61J 1/05 - Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids
Provided are a novel cancer treatment method and immunostimulant which exhibit a remarkably excellent antitumor effect with little side effects. An antitumor agent and an immunostimulant include an azabicyclo compound and an immune checkpoint molecule regulator which are administered in combination.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Provided is a method of treating malignant tumor by an azabicyclic compound, particularly, with eye disorder reduced. The present invention provides a method for treating malignant tumor, comprising administering an effective amount of 3-ethyl-4-[3-(1-methylethyl)-4-[4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl]-1H-pyrazolo[3,4-b]pyridin-1-yl]benzamide (compound 1) or a salt thereof to a patient in need thereof according to a dosing regimen, wherein the dosing regimen comprises administering the compound 1 or the salt thereof at a dose from 40 mg/body/day to 240 mg/body/day in terms of the amount of the compound 1 for consecutive days, and then providing a withdrawal period of at least 2 days.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 9/00 - Medicinal preparations characterised by special physical form
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Maintaining patient medical records and files in preparation
for surgery. Education, namely, training in the use and operation of
medical and surgical equipment, apparatus and appliances and
instruments, and consultation relating to the selection and
use thereof to provide medical care, medical therapy and
surgery. Medical research services; providing an online computer
database, namely, a repository of information in the field
of medical clinical studies and medical research via medical
case studies, peer-reviewed medical journal articles and
medical references (term considered too vague by the
International Bureau pursuant to Rule 13 (2) (b) of the
Regulations). Providing medical information, consultancy and advisory
services; professional consultation in the field of the use
of medical and surgical equipment, apparatus, appliance and
instruments; consultation on medical care, medical therapy
and surgery; consultation services, namely, providing
medical information to medical professionals to assist in
the diagnosis and treatment of patients; medical
consultation with physicians regarding the use of medical
apparatus for treatment of patients; technical consultation
in the field of medical and surgical equipment, apparatus,
appliances and instruments, namely, consultation regarding
their use in providing medical care, medical therapy and
surgery; providing a patient support program, namely,
providing medical information to patients evaluating
therapeutic treatment options; providing medical information
to patients in the field of surgery preparation; providing
an on-line computer database, namely, a repository of
information in the field of medical information and
healthcare information accessible to healthcare providers
including case studies, peer-reviewed journal articles and
references (term considered too vague by the International
Bureau pursuant to Rule 13 (2) (b) of the Regulations);
providing online medical evaluation services, namely,
functional assessment program for patients who are about to
receive medical treatment services for purposes of guiding
treatment and assessing program effectiveness; home health
care services in the nature of interactive medical care
monitoring for patients; managed healthcare services,
namely, providing disease management programs to others;
consultation relating to the use of medical and surgical
equipment, apparatus and appliances and instruments in
medical care, medical therapy and surgery; providing an
internet website for medical professionals and patients
featuring medical information from remote locations via
electronic patient monitoring devices that feed information
to the website that can be accessed in real-time by medical
professionals for purposes of monitoring and diagnosing
medical conditions (term considered too vague by the
International Bureau pursuant to Rule 13 (2) (b) of the
Regulations).
93.
PROCESSES FOR MAKING INTERMEDIATES FOR ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY
The present disclosure relates to processes for preparing synthetic intermediates for the synthesis of isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity.
C07D 309/06 - Radicals substituted by oxygen atoms
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
Provided is a novel chimeric antigen receptor. This chimeric antigen receptor includes an scFv region having such a structure that the C-terminus of a heavy-chain variable region and the N-terminus of a light-chain variable region are linked to each other through a linker, wherein: the heavy-chain variable region includes a heavy-chain CDR1 having the amino acid sequence represented by SEQ ID NO: 1, a heavy-chain CDR2 having the amino acid sequence represented by SEQ ID NO: 2, and/or a heavy-chain CDR3 having the amino acid sequence represented by SEQ ID NO: 3, and/or the light-chain variable region includes a light-chain CDR1 having the amino acid sequence represented by SEQ ID NO: 5, a light-chain CDR2 having the amino acid sequence represented by SEQ ID NO: 6, and/or a light-chain CDR3 having the amino acid sequence represented by SEQ ID NO: 7; and the number of amino acid residues constituting the linker is 15-50.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
This invention provides an antibody that binds specifically to sulfated glycosaminoglycan (sGAG) in a pH-dependent manner. The antibody that binds specifically to sulfated glycosaminoglycan is at least one antibody selected from the group consisting of (1) to (3): (1) an antibody comprising a heavy chain that comprises CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 1, CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 2, and CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 3 and a light chain that comprises CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 4, CDR2 consisting of the amino acid sequence represented by LGS, and CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 6; (2) an antibody comprising a heavy chain that comprises CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 7, CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 8, and CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 9 and a light chain that comprises CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 10, CDR2 consisting of the amino acid sequence represented by AAS, and CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 12; and (3) an antibody comprising a heavy chain that comprises CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 13, CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 14, and CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 15 and a light chain that comprises CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 16, CDR2 consisting of the amino acid sequence represented by WAS, and CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 18.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Provided is a novel method for treating cancer using an HSP90 inhibitor which exhibits a markedly superior antitumor effect and has a reduced side effect.
Provided is a novel method for treating cancer using an HSP90 inhibitor which exhibits a markedly superior antitumor effect and has a reduced side effect.
An antitumor agent is characterized in that an azabicyclo compound of the following Formula (1) or a salt thereof is administered in combination with other antitumor agent (s).
Provided is a novel method for treating cancer using an HSP90 inhibitor which exhibits a markedly superior antitumor effect and has a reduced side effect.
An antitumor agent is characterized in that an azabicyclo compound of the following Formula (1) or a salt thereof is administered in combination with other antitumor agent (s).
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
The present disclosure relates to pharmaceutical compositions comprising a solid dispersion comprising a compound of Formula (I): (I), or a pharmaceutically acceptable salt thereof, as well as methods of treatment.
Provided is a binder composition for an all-solid-state battery in which an inorganic binder component is used and which enables the formation of a solid electrolyte layer capable of allowing an all-solid-state battery to exert excellent ionic conductivity. A binder composition for an all-solid-state battery is used in formation of an all-solid-state battery and contains a flaky metal acid compound, wherein the flaky metal acid compound is composed of: a flaky metal acid; and a basic compound and/or a lithium salt.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of tumor; pharmaceutical preparations for the treatment of cancer; anti-cancer preparations; tumor suppressing agents; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for the treatment of cardiovascular diseases and disorders; pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical preparations for the treatment of dermatological diseases and disorders; pharmaceutical preparations for the treatment of muscular diseases and disorders; pharmaceutical preparations for the treatment of urological diseases and disorders; pharmaceutical preparations for the treatment of digestive diseases and disorders; pharmaceutical preparations for the treatment of gastroesophageal reflux diseases and disorders; pharmaceutical preparations for the treatment of hepatic diseases and disorders; pharmaceutical preparations for the treatment of renal diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of immune diseases and disorders; pharmaceutical preparations for the treatment of diseases of the central and peripheral nervous system; pharmaceutical preparations for the treatment of rheumatoid arthritis; pharmaceutical preparations for the treatment of diseases of the blood; pharmaceutical preparations for treating hematological disorders; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for use in chemotherapy; anti-emetic medicines; pharmaceutical preparations for the treatment of pain; analgesic preparations; antiphlogistic preparations; chemical preparations for pharmaceutical purposes; diagnostic reagents for medical purposes in the field of oncology.
A plant-based food product is provided with improved properties is provided. The plant-based food product comprises a partially hydrolyzed and fermented vegetable protein, a viscosity modifier and a vegetable oil. A method of making the plant-based food product is also provided.
